Malachite Innovations, Inc. (MLCT)
ValueMarkers Composite Index
DCF data not available
Malachite Innovations, Inc. (MLCT) — VMCI valuation read
MLCT prints VMCI 40/100 inside the Healthcare sector, where the median sits at 50. The 10-point below-median delta is the cleanest single-number summary of Malachite Innovations, Inc.'s composite stance, and in the mid-cap bucket it places the share behind the typical peer on the five-pillar mix.
On MLCT, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.
**Investor frame.** MLCT trades at 24.0x earnings, 33% above the Healthcare median of 18.0x; that is the value line. ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 2.8x is the rate-sensitivity line to watch; that is the risk line for Malachite Innovations, Inc. on the trailing financials.
MLCT fell 1.4% over the trailing 7 days, with a -11.0% read on a 30-day basis.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.
- CORBF - Global Cord Blood Corporation
- CORBF - Global Cord Blood Corporation
- 688555.SS - Essence Information Technology Co., Ltd.
- ATRA - Atara Biotherapeutics, Inc.
- ATRA - Atara Biotherapeutics, Inc.
- 0HIY.L - Atara Biotherapeutics, Inc.
- FPCG - First Physicians Capital Group, Inc.
- FPCG - First Physicians Capital Group, Inc.